[CNTB]

Its share price surged following the release of positive clinical data for chronic obstructive pulmonary disease (COPD) by Connect Biopharma. To put it bluntly, I will take profit upon reaching the resistance level near $2.93, and cut losses if the support level at $0.98 collapses. If I were to enter at this point, I would target a rebound buying opportunity in the extreme oversold zone of an RSI of 16.0; however, since the 20-day moving average is not yet aligned, I would respond by monitoring whether it breaks through the resistance level ($2.93) and checking for an increase in trading volume. In conclusion, while a rebound-driven buying surge from extreme oversold territory can be expected, a cautious approach is required given the unaligned moving averages and low trading volume. As of September 29, 2026, the closing price of $0.99 is very close to the $0.98 support level, accompanied by a -22.5% change over the past 7 days and an extreme oversold RSI of 16.0. However, because the 20-day moving average is not aligned and trading volume remains sluggish at 0.73 times the 20-day average, we must monitor whether a rebound toward the $2.93 resistance level occurs while confirming defense at the $0.98 support level. Technical indicators at the time of entry are as follows: RSI(14) stands at 16.0, indicating an extreme oversold condition, and the moving averages are in a non-bullish alignment. Volume is below average at 0.73 times the 20-day average, and the 7-day volatility (rate of change) recorded -22.5%. To conclude, a rebound from an extreme oversold condition was expected, but it failed to overcome the limitations of unaligned moving averages and low volume, ultimately reaching the stop-loss level. At the time of entry, a projected return of 4.5% was set based on the extreme oversold zone with an RSI(14) of 16.0 and bargain hunting near the support line ($0.98); however, it actually recorded a loss of -11.3%, resulting in a FAILED rating. What was missed was that with the 20-day moving average unaligned and sluggish trading volume at a mere 0.73 times the 20-day average, it was insufficient to defend against downward pressure. To put it bluntly, for future trades, rather than entering based solely on oversold indicators, I will apply stricter filters regarding volume increases and bullish moving average alignments. Even if the RSI is low and looks attractive, if volume fails to support the move and the price remains below the 20-day moving average, I will withhold entry—even near the support line ($0.98)—or strictly apply a confirmation-trading principle to manage potential losses.